Orchid Pharma, based in Chennai, has announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.

In a landmark collaboration, Orchid Pharma has partnered with Mumbai-based pharma company Cipla to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in the fight against AMR, a growing global health issue, reinforcing India’s leadership in medical innovation.

Orchid Pharma and Cipla are confident that this collaboration will set a new benchmark for addressing critical healthcare challenges through strategic partnerships and advanced research.

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India as quickly and efficiently as possible.